TRVI · Trevi Therapeutics, Inc.

Current Thesis

The de-risking binary is behind this name, not ahead of it. Haduvio's pivotal-grade efficacy signal landed with the positive CORAL Phase 2b in IPF chronic cough (June 2, 2025) and was ratified by a JAMA publication in January 2026. An April 2026 raise pushed cash to $171.8M and runway into 2030. What is left is a single-asset clinical-stage biotech trading near 52-week highs with no idiosyncratic data event for roughly 14 months the next toplines land in H2 2027, the first Phase 3 IPF readout not until H1 2028. The +136% trailing-year move already paid out the validation. With the catalyst clock dead until late 2027 and the April $13.00 offering acting as the operative floor, a fresh entry here buys a $13–16 consolidation with no momentum trigger. Better to stand aside until either a fresh-high breakout or a real data window approaches.

Bull Case

• CORAL Phase 2b topline (2025-06-02): 60.2% reduction in 24-hour cough frequency at 108mg BID vs 16.9% on placebo, p<0.0001, placebo-adjusted −43.3%, n=165 IPF patients across four arms a validated mechanism rather than a de-novo biology gamble.
• Peer-review ratification: full CORAL results published in JAMA (January 2026), lowering perception and regulatory-credibility risk ahead of Phase 3.
• Balance sheet (Q1 2026, reported 2026-05-05): $171.8M cash and marketable securities ($19.4M cash + $152.4M securities), guided runway into 2030 funded through every planned Phase 3 initiation without a near-term forced raise.
• Competitive void: no approved therapy for chronic cough in IPF; Merck's gefapixant (P2X3) drew a CRL in 2024, leaving nalbuphine's kappa-agonist/mu-antagonist profile the front-runner.
• Multiple shots on goal: two Phase 3 IPF cough trials (initiating Q2 and H2 2026), an RCC Phase 2b (initiating Q2 2026), and a non-IPF ILD Phase 2b (H2 2026) widen the addressable cough population well beyond IPF.

Bear Case

• Catalyst desert: the next clinical topline is H2 2027 (RCC Phase 2b, the second Phase 3 IPF trial, non-IPF ILD), with the first Phase 3 IPF readout pushed to H1 2028. For ~14 months the tape has no company-specific data driver and drifts on sector flow.
• The asymmetry is spent: the +136% trailing-year run (to ~$15.27 on 2026-05-13) already discounted the CORAL de-risking; entries near $13–16 do not get the setup that existed at $5–8 in 2025.
• Dilution machinery armed: on 2026-06-03 shareholders doubled authorized shares from 200M to 400M and added 8M to the incentive plan. Even with runway into 2030, the structural capacity to issue caps multiple expansion.
• Single-asset binary intact: Haduvio is the company. A Phase 3 IPF miss in 2027–2028 is a 60–80% drawdown scenario on standard small-cap biotech math.
• Burn rising into Phase 3: Q1 2026 net loss of $13.2M vs $10.3M in Q1 2025 as trial spend ramps.
• Structurally pinned: trading near the $16.12 52-week high with the April $13.00 print as a near floor leaves limited room to resistance and real air below.

Setup & Price Structure

• Last ~$13.33 (2026-06-07); 52-week range $5.41–$16.12; market cap ~$1.89B (~142M shares); session volume ~690K.
• April 2026 offering cleared at $13.00 (net proceeds ~$162M). That print is the operative floor: closes holding above it keep post-deal structure intact, a close below flips supply against the tape.
• Range-bound $13–16 since the raise, off the May $16.12 high no momentum acceleration, no fresh-high breakout, no stretched parabolic extension to fade.
• Re-engagement condition: a decisive break and hold above $16.12 on expanding volume, which would signal the market front-running Phase 3 success ahead of data. That is not the current condition.
• Breakdown condition: a daily close below $13.00; loss of ~$12 confirms post-deal supply bleed.

Catalyst Calendar (next 30 days)

• ~2026-06-30 (Q2 guidance deadline): first Phase 3 IPF chronic cough trial initiation and the RCC Phase 2b trial initiation are both guided for Q2 2026. These are operational trial-start disclosures, not data modest impact, no binary.
• No clinical readout in the window. The next interim event is the RCC Phase 2b sample-size re-estimation in Q4 2026; the next toplines are H2 2027.
• ~2026-08 (est.): Q2 2026 financial results and business update (Q1 reported 2026-05-05) outside the 30-day window but the next scheduled corporate update; watch for any change to runway guidance or Phase 3 enrollment pace.

What Would Change Our Mind

• Bullish re-rate: a decisive break and hold above the $16.12 52-week high on expanding volume, signaling the market is discounting Phase 3 success roughly a year ahead of data that would convert the catalyst desert into an accumulation setup rather than a reason to wait.
• Pulled-forward catalyst: an 8-K accelerating any topline into 2026 (unlikely given current guidance), or a positive non-IPF ILD FDA-meeting outcome that enables earlier indication expansion.
• Bearish invalidation: a daily close below the $13.00 offering anchor signals post-deal supply control is lost; below ~$12 confirms the breakdown. Any 8-K disclosing a Phase 3 clinical hold, protocol amendment, SAE cluster, or despite the runway-into-2030 guide a fresh equity raise (the doubled share authorization is the enabling mechanism) ends the constructive read outright.

Correlation Notes

• High beta to XBI and the broader small-cap biotech tape. With no idiosyncratic catalyst for ~14 months, sector flow dominates daily price action; XBI-driven moves carry no TRVI-specific signal and should not be read as thesis confirmation either way.
• Mechanistic read-through to the chronic-cough/antitussive complex Merck's gefapixant (P2X3, post-CRL) and Bayer/competitor camlipixant-class programs. Competitor cough data is a swing factor for the addressable-market narrative.
• Single-asset structure means idiosyncratic 8-K risk (clinical, regulatory, financing) eventually overwhelms macro as a catalyst nears; until then, rate-sensitive small-cap biotech flows (XBI, IBB) set the trading range.